Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / June / Testing Atropine's Posterior Effects
Practice Management Refractive News

Testing Atropine’s Posterior Effects

Low-dose atropine shows limited short-term posterior structural effects in young adults

6/12/2026 2 min read

Share

  • Full Article
  • Summary
  • Listen
  • Report
  • Quiz
  • Top Institutions
  • Topic Commentary
5 Topic Commentaries

Testing Atropine’s Posterior Effects

Testing Atropine’s Posterior Effects

  • Lisa A. Ostrin
    Lisa A. Ostrin, OD, PhD, FAAO, FARVO

    Optometry; Vision Science; Myopia research

    •

    University of Houston College of Optometry

    These findings indicate that a single instillation of atropine does not alter axial length or retinal or choroidal thickness over 24 hours but may transiently affect superficial retinal perfusion in a time-dependent manner,” said Ostrin.

    Source
  • Karla Zadnik
    Karla Zadnik, OD, PhD

    Optometry; Myopia

    •

    The Ohio State University College of Optometry

    “The .01% story is clearer and more obvious in terms of significantly slowing both the growth of the eye as well as then resulting in a lower glasses prescription,” Zadnik said.

    Source
  • Michael F. Chiang
    Michael F. Chiang, MD

    Ophthalmology; Pediatric Ophthalmology; Clinical Informatics

    •

    National Eye Institute, National Institutes of Health

    “The overall mixed results on low-dose atropine show us we need more research. Would a different dose be more effective in a US population? Would combining atropine with other strategies have a synergistic effect? Could we develop other approaches to treatment or prevention based on a better understanding of what causes myopia progression?”

    Source
  • Michael X. Repka
    Michael X. Repka, MD, MBA

    Pediatric Ophthalmology; Strabismus

    •

    Johns Hopkins University School of Medicine (Wilmer Eye Institute)

    “The absence of a treatment benefit in our U.S.-based study, compared with East Asian studies, may reflect racial differences in atropine response. The study enrolled fewer Asian children, whose myopia progresses more quickly, and included Black children, whose myopia progresses less quickly compared with other races,”

    Source
  • Katherine K. Weise
    Katherine K. Weise, OD, MBA, FAAO

    Pediatric Optometry; Myopia

    •

    University of Alabama at Birmingham School of Optometry

    “Clinical researchers could evaluate new pharmaceuticals and special wavelengths of light in combination with optical strategies, like special glasses or contact lenses, to see what works in reducing the progression of myopia.”

    Source

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: